NEWS: 公告在东京证券交易所JASDAQ标准市场新上市

表纸
市场调查报告书

间充质干细胞:进展与应用(2021)

Mesenchymal Stem Cells - Advances and Applications, 2021

出版商 BIOINFORMANT WORLDWIDE, LLC 商品编码 986212
出版日期 内容资讯 英文 276 Pages
订单完成后即时交付
价格
间充质干细胞:进展与应用(2021) Mesenchymal Stem Cells - Advances and Applications, 2021
出版日期: 2021年04月13日内容资讯: 英文 276 Pages
简介

作为当今再生医学中最常用的干细胞类型,它在间充质干细胞(MSC)市场中具有巨大的增长潜力。已经为MSC出版了100,000多个科学出版物,并且全世界正在进行1100多个MSC临床试验。 MSC临床试验的当前 "热点" 包括美国,欧盟,中国,中东和韩国。尽管许多早期MSC试验已经证明了安全性和有效性,但是很少有MSC产品被商业化,这表明MSC治疗市场仍处于早期阶段。人口老龄化和慢性病患病率上升也使人们对基于MSC的疗法越来越感兴趣。此外,根据Google趋势数据,MSC搜索的普及率是次最常见的干细胞类型的两倍以上。近年来,对MSC和基于MSC的研究产品的需求都猛增。

本报告调查了全球间充质干细胞(MSC)市场,并详细分析了98家主要公司的活动,以及按地区和业务领域划分的五年市场预测和市场规模,并提供了详细的数据。

目录

第1章报告概述

  • 报告声明
  • 目标受众特征
  • 报告来源
  • 报告目的
  • 执行摘要
  • 简介

第2章间充质干细胞(MSCS):概述

  • MSC对再生医学的影响
  • MSC命名时间线
  • MSC来源
    • 骨髓来源的MSC(BM-MSC)
    • 脂肪来源的MSC(AD-MSC)
    • 脐带来源的MSC(UC-MSC)
  • MSC细胞表面标记
  • MSC体外分化潜能
  • MSC分泌的可溶性因子

第3章间充质干细胞的产生

  • MSC分离方法
  • 从常规培养到生物反应器
    • 单层培养系统
    • 基于生物反应器的细胞增殖
    • 搅拌槽式生物反应器
    • 锁定生物反应器
    • 中空纤维生物反应器
    • 固定地板生物反应器
    • 细胞分离与分离
    • 细胞洗涤和浓缩
    • 安全性和有效性测定
    • 用于在MSC制造过程中进行识别的表面标记

第4章内部和同源MSC生产的比较

  • 制造成本比较
    • 成本差异
    • 捐助者筛选和测试费用
    • 发布测试成本
  • 两种商业模式的比较
    • 免疫反应的风险
    • 相互污染的风险
    • 具有商业吸引力的选择
  • MSC制造成本明细
  • 降低成本的机会
  • 部分自动化和完全自动化
    • 部分自动化:最有吸引力的选择

第5章MSCS的小规模处理

  • 模型设计

第6章MSCS的大规模扩展

  • 四种常见的大规模扩展生物加工策略
  • 通常用于大规模扩展的MSC来源
  • MSC大规模扩展常用的介质
    • 在不同媒体上实现的起泡率
  • 大规模生物加工策略的比较
  • 细胞疗法的外包生产
    • 合同制造组织(CMO)
    • 合同开发与制造组织(CDMO)
  • 世界细胞疗法制造能力
    • 美国主要细胞疗法CMO/CDMO
    • 用于欧洲细胞疗法生产的主要CMO/CDMO

第7章行业中MSCS的估计消耗量

  • 在学术和临床前环境中使用MSC
  • 在临床实践中使用MSC
  • 在临床试验中通过靶标指示消耗MSC
  • 未来消费预测
    • MSC治疗的消耗
    • 人造组织和器官的消耗
    • MSC衍生产品的MSC消耗
    • 新兴行业中的MSC消费
  • 临床试验中每位患者使用MSC的费用:按适应症

第8章在MSCS上发表的科学论文

  • MSC和iPSC上的论文数量比较
  • 关于MSC的论文数量:按来源
  • 在临床试验中发表的文章数量,包括MSC
    • 关于使用MSC治疗特定疾病的临床试验的论文数量

第9章MSCS,基于MSC的COVID-19,MSC-外泌体临床试验

  • ClinicalTrials.gov的数据分析
  • MSC临床试验来源
  • MSC与自己的MSC相似
  • 基于MSC的临床试验的区域分布
    • 参与基于MSC的临床试验的主要国家
  • 基于MSC的临床试验的资金类型
  • 基于MSC的临床试验的类型
  • 基于MSC的开发阶段临床试验
  • 涉及MSC治疗COVID-19的临床试验
    • 基于MSC的COVID-19临床试验:按地区
  • 涉及MSC来源的外泌体的临床试验
  • NIH为MSC研究提供资金
  • CIRM为MSC项目提供的资金
    • CIRM资助基于MSC的临床试验

第10章当前的次优临床结果和解决方案

  • 克服MSC制造带来的挑战
    • MSC产品不均匀
  • 冷冻保存和文化救援
    • 增强MSC功能的生物工程解决方案
    • MSC工程部运送抗癌药物 "Trogan Horses"
  • 克服与输液有关的临床挑战
    • 地方行政
    • 保留和存活不足
    • 改善地方行政管理的策略
  • 克服宿主的临床挑战

第11章MSCS更改

  • 转基因
    • 基因改造可改善迁徙
    • 基因改造,以提高附著力
    • 基因改造可提高生存率
    • 基因改造可减少过早衰老
  • 更改预处理
    • 预处理以改善迁移
    • 预处理以提高粘合性
    • 预处理以提高生存率
    • 减少老化的预处理
  • 改良的MSC的治疗应用
    • 改良的MSC用于神经系统疾病
    • 用于心血管疾病的改良MSC
    • 改良的MSC用于肺损伤
    • 用于糖尿病的改良型MSC

第十二章MSCS在临床试验中解决的主要疾病

  • 使用MSC治疗自身免疫性疾病的临床试验
  • 使用MSC治疗心血管疾病的临床试验
  • 使用MSC治疗神经退行性疾□□病的临床试验
  • 使用MSC治疗骨骼和软骨疾病的临床试验

第13章间充质干细胞产业的现状

  • 用于研究和临床应用的MSC来源
  • 受到关注的相似和异构产品
  • 具有营销许可的基于MSC的产品
    • Alofisel
    • Stemirac
    • Stempeucel
    • Temcell HS
    • Neuronata-R
    • Prochymal (Remestemcel-L)
    • Cupistem
    • Cartistem
    • Cellgram-AMI
    • Queencell
  • 基于MSC的骨基质目前正在销售中
    • Osteocel
    • AlloStem
    • Cellentra VCBM
    • HiQCell
    • Trinity ELITE
    • Map3
    • Trinity Evolution
    • Carticel
    • Chondron
    • DeNovo NT
    • Chondrocelect
    • Ossron
    • JACC
    • MACI
    • Ortho-ACI
    • Spherox
    • Ossgrow
    • Cartigrow
    • ViviGen
    • Bio4
    • Cartiform
  • 从全细胞MSC治疗到MSC衍生的外泌体治疗
    • MSC来源的外泌体的优势
    • 来自MSC的外泌体的含量
    • 外来体作为诊断
    • 外来体作为药物传递载体
  • 基于MSC的COVID-19处理
  • 基于MSC的清洁肉生产
  • 干细胞型化妆品
    • 市售干细胞化妆品

第14章市场分析

  • 基于MSC的细胞疗法(CT)治疗的价格标签
  • 基于MSC的矩阵价格标签
  • 基于MSC的疗法的市场规模
  • 基于MSC的疗法的全球市场
  • 对间充质干细胞(MSC)的全球需求
    • 学术和临床前研究所需的MSC
    • 临床试验所需的MSC
    • MSC需要开发基于MSC的疗法
    • 开发MSC衍生产品所需的MSC
    • 新兴行业所需的MSC
    • 间充质干细胞的全球市场规模
  • 基于MSC的业务领域的市场份额

第15章公司简介

  • 101 Bio
  • Adipomics, Inc.
  • Aegle Therapeutics
  • Aethlon Medical, Inc.
  • AgeX Therapeutics, Inc.
  • Alexerion Biotech Corp.
  • AlloSource, Inc.
  • American CryoStem Corporation
  • American Type Culture Collection (ATCC)
  • AMS Bio, Ltd. (AMSBIO)
  • Anemocyte S.r.l
  • Anjarium Biosciences
  • Anterogen, Co., Ltd.
  • Apceth Biopharma GmbH
  • Assay Development
  • Aruna Bio
  • Athersys, Inc.
  • Avalon GloboCare Corp.
  • Axol Bioscience, Ltd.
  • Azymus Therapeutics
  • BioCat GmbH
  • BioFluidica
  • Bio-Techne
  • BioVision, Inc.
  • Baylx, Inc.
  • BrainStorm Cell Therapeutics
  • Capricor Therapeutics
  • Catalent Pharma Solutions
  • CCRM
  • CellResearch Corporation, Pte Ltd.
  • Celltex Therapeutics Corporation
  • Ciloa
  • Codiak Biosciences
  • Corestem, Inc.
  • CO-DON AG
  • Cognate Bio, Inc.
  • Creative Bioarray
  • Creative Biolabs
  • Cynata Therapeutics, Ltd.
  • DePuy Synthes
  • Direct Biologics
  • EVerZom
  • Evox Therapeutics, Ltd.
  • Exerkine Corp.
  • Clinical Development
  • ExoCan Healthcare Technologies, Pvt. Ltd.
  • ExoCoBio, Co., Ltd.
  • Exogenus Therapeutics
  • EXoPERT
  • Exopharm
  • Exosome Diagnostics, Inc.
  • ExoDx Prostate Test
  • ExosomePlus
  • Exosome Sciences
  • Exosomics S.p.A
  • Fraunhofer Institute for Cell Therapy and Immunology
  • HansaBioMed Life Sciences, Ltd.
  • Hope Biosciences, LLC
  • Hope's Cell Culture Process
  • Japan Tissue Engineering, Co., Ltd.
  • JCR Pharmaceuticals, Co., Ltd.
  • Kimera Labs, Inc.
  • Lonza Group Ltd.
  • Mantra Bio
  • Medipost, Co., Ltd.
  • MDimune
  • NanoSomix, Inc.
  • NanoView Biosciences
  • NeurExo Sciences
  • Nipro Corporation
  • Stemirac
  • Novus Biologicals, LLC
  • Exosomes Research Tools
  • NuVasive, Inc.
  • Osteocel Family
  • OmniSpirant Limited
  • Orthocell, Ltd.
  • Orthofix Medical, Inc.
  • Osiris Therapeutics, Inc.
  • Pharmicell, Co., Ltd.
  • Pluristem Therapeutics, Inc.
  • Regeneus, Ltd.
  • HiQCell
  • Regrow Biosciences, Pvt., Ltd.
  • ReNeuron
  • RoosterBio
  • RoslinCT
  • RTI Surgical, Inc.
  • Sentien Biotechnologies, Inc.
  • STEMCELL Technologies, Inc.
  • Stemedica Cell Technologies, Inc.
  • Stemmatters Biotechnologia e Medicina Regenerative SA
  • Stempeutics Research, Pvt., Ltd.
  • System Biosciences, LLC
  • Takeda Pharmaceuticals U.S.A., Inc.
  • Alofisel
  • Tempo Bioscience
  • Tavec Pharma
  • United Therapeutics Corp.
  • Vericel Corporation
  • Versatope Therapeutics
  • Vesigen Therapeutics, Inc.
  • Waisman Biomanufacturing
  • WuXi Advanced Therapies
  • XOStem, Inc.
  • Zen-Bio, Inc.
  • Zimmer Biomet
目录

EXECUTIVE SUMMARY

Mesenchymal stem cells (MSCs) are multipotent cells that can differentiate into a variety of cell types, including but not limited to osteoblasts, chondrocytes, myocytes, and adipocytes. In addition to secreting factors that can stimulate tissue repair, MSCs can substantially alter their microenvironment, exerting effects that are both anti-inflammatory and anti-fibrotic. MSCs are advantageous over other stem cells types for a variety of reasons, including that they are immuno-privileged, making them an advantageous cell type for allogenic transplantation. MSCs appear to be an exceptionally promising tool for cell therapy, because of their unusual advantages, which include availability, expandability, transplantability, and ethical implications. Interest in therapeutic applications of human MSCs arises from their diverse ability to differentiate into a range of cell types, as well as their ability to migrate to sites of tissue injury/inflammation or tumor growth.

Naturally, a broad range of research products have been developed around MSCs and their differentiated cell types. Growing attention is also being given to manufacturing technologies to support commercial-scale production of MSCs. MSCs are well-suited for use in the exponential growth field of 3D printing, because of their capacity to form structural tissues. Numerous market competitors are exploring commercialization strategies for MSC-derived extracellular vesicles (Evs) and exosomes, because these extracellular "packages" represent a novel strategy for accessing the therapeutic effects of stem cells without the risks of administering whole cells to patients. Finally, gene editing of MSCs for overexpressing antitumor genes or therapeutic factors is broadening their application.

As the most common stem cell type being used within regenerative medicine today, there is huge potential for growth within the MSC market. There are more than one-hundred thousand scientific publications published about MSCs, as well over 1,100 MSC clinical trials underway worldwide. Current "hotspots" for MSC clinical trials include the U.S., E.U., China, Middle East, and South Korea. While many early-stage MSC trials have demonstrated safety and efficacy, only a small number of MSC products have reached commercialization, indicating that the therapeutic market for MSCs remains early-stage. Population aging and an increasing prevalence of chronic disease are also driving interest in MSC-based therapies. Furthermore, Google Trend data reveals that MSC searches are more than twice as common as the next most common stem cell type. The demand for both MSCs and MSC-based research products have surged in recent years.

Today in 2021, nearly one-hundred different market competitors are developing various types of MSC-related products/services, therapies, and manufacturing technologies. Within this ever-changing landscape, having a thorough understanding of the competition and their relative strengths and weaknesses is essential. Therefore, this global strategic report details the activities of 98 leading MSC companies. It also presents detailed market size figures for the global MSC market, segmented by geography and business segment, accompanied by five-year forecasts through 2027.

With the competitive nature of this global market, you do not have the time to do the research. Claim this report to become immediately informed, without sacrificing hours of unnecessary research or missing critical opportunities.

The main objectives of this report are to provide the reader with the following details:

  • Market size determination for the global MSC market, segmented by geography and business segment
  • Five-year forecasts for the global MSC market
  • Details of the product candidates being developed by MSC companies
  • MSC market trends, opportunities, risks, and competitive dynamics
  • Major diseases addressed by MSCs in the ongoing clinical trials
  • Cost of manufacturing autologous and allogeneic MSCs
  • Consumption of MSCs for academic research, clinical trials, product development, and exosome production
  • Trend rate data for MSC scientific publications
  • Rates, quantities, geographic locations, and types of MSC clinical trials
  • Types and sources of MSC industry funding
  • Recent business developments related to MSCs
  • MSC-based products with marketing approval and the companies commercializing them
  • Currently marketed MSC-based bone matrices
  • Pricing comparison of MSC-based products with marketing approval
  • Emerging applications for MSCs, including genetic modification, 3D bioprinting, clean meat production and cosmeceuticals
  • Company profiles for 98 MSC market competitors, including their proprietary technologies and products/services under development
  • And so much more

For more comprehensive details about the contents of this report, view the Table of Contents, List of Figures, and List of Tables.

With an online readership of nearly one million viewers per year, BioInformant is a U.S. market research firm with 15 years of experience. As the first and only market research firm to specialize in the stem cell industry, BioInformant research has been cited by the Wall Street Journal, Xconomy, and Vogue Magazine. Founded in 2006 and headquartered in Washington, DC, BioInformant is strategically positioned to be near the National Institutes of Health (NIH), the U.S. FDA, the Maryland Biotech Corridor, and policy makers on Capitol Hill. In addition to leveraging an experienced team of analysts, BioInformant's has unparalleled access to key opinion leaders (KOLs) from across the stem cell sector.

To analyze the rapidly evolving stem cell sector, BioInformant conducts ongoing interviews with prominent executives from across the field. To assess MSC market dynamics, BioInformant interviewed representatives from Cynata Therapeutics (first company to bring an iPSC-derived MSC therapeutic product into a clinical trial), RoosterBio (specializes in manufacturing tens of billions of MSCs in suspension bioreactors), Celularity, Inc. (developing MSC therapeutics from the post-partum human placenta), Pluristem Therapeutics (commercializing placenta-derived mesenchymal-like adherent stromal cells in late-stage clinical trials), BioEden (leading company preserving MSCs derived from dental tissues), Regenexx (world's leading provider of MSC therapies for orthopedic applications), and numerous others. As the first and only market research firm to specialize in the stem cell industry, BioInformant is your trusted leader in stem cell industry data.

EXECUTIVE SUMMARY

Mesenchymal stem cells (MSCs) are multipotent cells that can differentiate into a variety of cell types, including but not limited to osteoblasts, chondrocytes, myocytes, and adipocytes. In addition to secreting factors that can stimulate tissue repair, MSCs can substantially alter their microenvironment, exerting effects that are both anti-inflammatory and anti-fibrotic. MSCs are advantageous over other stem cells types for a variety of reasons, including that they are immuno-privileged, making them an advantageous cell type for allogenic transplantation. MSCs appear to be an exceptionally promising tool for cell therapy, because of their unusual advantages, which include availability, expandability, transplantability, and ethical implications. Interest in therapeutic applications of human MSCs arises from their diverse ability to differentiate into a range of cell types, as well as their ability to migrate to sites of tissue injury/inflammation or tumor growth.

Naturally, a broad range of research products have been developed around MSCs and their differentiated cell types. Growing attention is also being given to manufacturing technologies to support commercial-scale production of MSCs. MSCs are well-suited for use in the exponential growth field of 3D printing, because of their capacity to form structural tissues. Numerous market competitors are exploring commercialization strategies for MSC-derived extracellular vesicles (EVs) and exosomes, because these extracellular "packages" represent a novel strategy for accessing the therapeutic effects of stem cells without the risks of administering whole cells to patients. Finally, gene editing of MSCs for overexpressing antitumor genes or therapeutic factors is broadening their application.

As the most common stem cell type being used within regenerative medicine today, there is huge potential for growth within the MSC market. There are more than one-hundred thousand scientific publications published about MSCs, as well over 1,100 MSC clinical trials underway worldwide. Current "hotspots" for MSC clinical trials include the U.S., E.U., China, Middle East, and South Korea. While many early-stage MSC trials have demonstrated safety and efficacy, only a small number of MSC products have reached commercialization, indicating that the therapeutic market for MSCs remains early-stage. Population aging and an increasing prevalence of chronic disease are also driving interest in MSC-based therapies. Furthermore, Google Trend data reveals that MSC searches are more than twice as common as the next most common stem cell type. The demand for both MSCs and MSC-based research products have surged in recent years.

Today in 2021, nearly one-hundred different market competitors are developing various types of MSC-related products/services, therapies, and manufacturing technologies. Within this ever-changing landscape, having a thorough understanding of the competition and their relative strengths and weaknesses is essential. Therefore, this global strategic report details the activities of 98 leading MSC companies. It also presents detailed market size figures for the global MSC market, segmented by geography and business segment, accompanied by five-year forecasts through 2027.

With the competitive nature of this global market, you do not have the time to do the research. Claim this report to become immediately informed, without sacrificing hours of unnecessary research or missing critical opportunities.

The main objectives of this report are to provide the reader with the following details:

  • Market size determination for the global MSC market, segmented by geography and business segment
  • Five-year forecasts for the global MSC market
  • Details of the product candidates being developed by MSC companies
  • MSC market trends, opportunities, risks, and competitive dynamics
  • Major diseases addressed by MSCs in the ongoing clinical trials
  • Cost of manufacturing autologous and allogeneic MSCs
  • Consumption of MSCs for academic research, clinical trials, product development, and exosome production
  • Trend rate data for MSC scientific publications
  • Rates, quantities, geographic locations, and types of MSC clinical trials
  • Types and sources of MSC industry funding
  • Recent business developments related to MSCs
  • MSC-based products with marketing approval and the companies commercializing them
  • Currently marketed MSC-based bone matrices
  • Pricing comparison of MSC-based products with marketing approval
  • Emerging applications for MSCs, including genetic modification, 3D bioprinting, clean meat production and cosmeceuticals
  • Company profiles for 98 MSC market competitors, including their proprietary technologies and products/services under development
  • And so much more

For more comprehensive details about the contents of this report, view the Table of Contents, List of Figures, and List of Tables.

With an online readership of nearly one million viewers per year, BioInformant is a U.S. market research firm with 15 years of experience. As the first and only market research firm to specialize in the stem cell industry, BioInformant research has been cited by the Wall Street Journal, Xconomy, and Vogue Magazine. Founded in 2006 and headquartered in Washington, DC, BioInformant is strategically positioned to be near the National Institutes of Health (NIH), the U.S. FDA, the Maryland Biotech Corridor, and policy makers on Capitol Hill. In addition to leveraging an experienced team of analysts, BioInformant's has unparalleled access to key opinion leaders (KOLs) from across the stem cell sector.

To analyze the rapidly evolving stem cell sector, BioInformant conducts ongoing interviews with prominent executives from across the field. To assess MSC market dynamics, BioInformant interviewed representatives from Cynata Therapeutics (first company to bring an iPSC-derived MSC therapeutic product into a clinical trial), RoosterBio (specializes in manufacturing tens of billions of MSCs in suspension bioreactors), Celularity, Inc. (developing MSC therapeutics from the post-partum human placenta), Pluristem Therapeutics (commercializing placenta-derived mesenchymal-like adherent stromal cells in late-stage clinical trials), BioEden (leading company preserving MSCs derived from dental tissues), Regenexx (world's leading provider of MSC therapies for orthopedic applications), and numerous others. As the first and only market research firm to specialize in the stem cell industry, BioInformant is your trusted leader in stem cell industry data.

To analyze the rapidly evolving stem cell sector, BioInformant conducts ongoing interviews with prominent executives from across the field. To assess MSC market dynamics, BioInformant interviewed representatives from Cynata Therapeutics (first company to bring an iPSC-derived MSC therapeutic product into a clinical trial), RoosterBio (specializes in manufacturing tens of billions of MSCs in suspension bioreactors), Celularity, Inc. (developing MSC therapeutics from the post-partum human placenta), Pluristem Therapeutics (commercializing placenta-derived mesenchymal-like adherent stromal cells in late-stage clinical trials), BioEden (leading company preserving MSCs derived from dental tissues), Regenexx (world's leading provider of MSC therapies for orthopedic applications), and numerous others. As the first and only market research firm to specialize in the stem cell industry, BioInformant is your trusted leader in stem cell industry data.